Ventas, Inc. VTR shares have performed strongly over the past year and appear fully valued at present. However, Argus’ Jacob Kilstein prefers to wait for a non-fundamental pullback to become more constructive on the stock.
Kilstein initiated coverage of the company with a Hold rating.
Stock Outperformance
“We believe that Ventas has strong opportunities in the $1 trillion senior housing and healthcare real estate market, driven by favorable demographic trends, increased healthcare spending, and growing demand for low-cost medical outpatient facilities,” the analyst mentioned.
Over the past three months, the stock has outperformed the S&P 500, appreciating 14 percent, as compared to a 5 percent rise in the broad market.
The stock has also outperformed over the past year, gaining 11 percent, as compared to the 3 percent gain for the market.
Recent Acquisitions, Investments
Ventas acquired 23 medical and life science properties from Blackstone Group LP BX on July 5, for $1.5 billion.
Kilstein expects the deal to boost Ventas’ 2017 FFO by $0.07–$0.09 per share.
“During the first quarter, Ventas invested $154 million in new projects, including $140 million in life science properties in Massachusetts and California. The company also funded $37 million of development and redevelopment projects within its $500 million pipeline,” the analyst said.
The company issued 1.6 million in stock, which generated $101 million. The proceeds were used to help fund the various investments during the quarter.
Ventas also sold seven properties for a total profit of $69 million.
Did you like this article? Could it have been improved? Please email feedback@benzinga.com to let us know!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.